Takeda’s zasocitinib scored statistical superiority over Bristol Myers Squibb’s Sotyktu (deucravacitinib) in a top-line Phase 3 readout for moderate-to-severe plaque psoriasis, reported from the Latitude Atlas program. Takeda said the superiority held on primary and secondary goals, positioning its oral TYK2 inhibitor to challenge the current standard-of-care landscape. The result adds urgency for payers and clinicians weighing injectable vs oral options in psoriasis as multiple oral and pipeline TYK2 assets vie for market share.